Common variation in the sodium/glucose cotransporter 2 gene SLC5A2 does neither affect fasting nor glucose-suppressed plasma glucagon concentrations
Open accessAbstract
AIM: Inhibition of sodium/glucose cotransporter 2 (SGLT2), the key transport protein in renal glucose reabsorption, promotes glucose excretion and represents a new concept in the therapy of type-2 diabetes. In addition, SGLT2 inhibition elevates circulating glucagon concentrations and enhances hepatic glucose production. Since SGLT2 is expressed in human pancreatic α-cells and regulates glucagon release, we tested whether common variants of the SGLT2 gene SLC5A2 associate with altered plasma glucagon concentrations in the fasting state and upon glucose challenge. METHODS: A study population of 375 healthy subjects at increased risk for type-2 diabetes, phenotyped by a 5-point oral glucose tolerance test (OGTT) and genotyped for recently described SLC5A2 tagging single nucleotide polymorphisms (SNPs), was selected for plasma glucagon measurements. RESULTS: After adjustment for gender, age, body mass index, and insulin sensitivity, the four tagging SNPs (rs9924771, rs3116150, rs3813008, rs9934336), tested separately or as genetic score, were neither significantly nor nominally associated with plasma glucagon concentrations at any time during the OGTT, with the inverse AUC of glucagon or the glucagon fold-change during the OGTT (p ≥ 0.2, all). Testing for genotype-related differences in the time course of the glucagon response using MANOVA did also not reveal any significant or nominal associations (p ≥ 0.5, all). CONCLUSION: We could not obtain statistically significant evidence for a role of common SLC5A2 variants in the regulation of glucagon release in the fasting state or upon glucose challenge. Moreover, the reported nominal effects of individual SLC5A2 variants on fasting and post-challenge glucose levels may probably not be mediated by altered glucagon release.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
SLC5A2 (which encodes SGLT2) can be used to instrument therapeutic inhibition of SGLT2 for multiple endpoints related to metabolic and vascular disease.
“SLC5A2 (which encodes SGLT2) to instrument therapeutic inhibition of SGLT2 120 for multiple endpoints related metabolic and vascular disease 123,124 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [124]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · see citing works
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · see citing works
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795 · see citing works
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670 · see citing works
Glucose handling by the kidney
Mather, A., & Pollock, C. A. (2011) · Kidney International · doi:10.1038/ki.2010.509 · Cited by 376 · see citing works
The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
Vallon, V. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-051013-110046 · Cited by 349 · see citing works
Stefan, N., Machicao, F. E., Staiger, H., Machann, J., Schick, F., Tschritter, O., Spieth, C., Weigert, C., Fritsche, A., Stümvoll, M., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1948-3 · Cited by 186 · see citing works
Self-citationPoulsen, S. B., Fenton, R. A., & Rieg, T. (2015) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0000000000000152 · Cited by 164 · see citing works
Evaluation of Glucose Homeostasis
Heikkinen, S., Argmann, C., Champy, M., & Auwerx, J. H. (2007) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb29b03s77 · Cited by 125 · see citing works
(1983) · Comprehensive biochemistry · doi:10.1016/b978-0-444-80507-2.50002-8 · Cited by 62 · see citing works
Zimdahl, H., Haupt, A., Brendel, M., et al. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000268 · Cited by 48 · see citing works
Enigk, U., Breitfeld, J., Schleinitz, D., Dietrich, K., Halbritter, J., Fischer‐Rosinsky, A., Enigk, B., Müller, I., Spranger, J., Pfeiffer, A. F. H., et al. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.69 · Cited by 37 · see citing works
Nonsuppressed Glucagon After Glucose Challenge as a Potential Predictor for Glucose Tolerance
Wagner, R. J., Hakaste, L., Ahlqvist, E., Heni, M., Machann, J., Schick, F., OBBERGHEN, E. V., Stefan, N., Gallwitz, B., Tuomilehto, J., et al. (2016) · Diabetes · doi:10.2337/db16-0354 · Cited by 37 · see citing works
Self-citationDusaulcy, R., Handgraaf, S., Heddad-Masson, M., Visentin, F., Vesin, C., Reimann, F. M., Gribble, F. M., Philippé, J., & Gosmain, Y. (2015) · Endocrinology · doi:10.1210/en.2015-1725 · Cited by 22 · see citing works
The Road to Ion-coupled Membrane Processes
Crane, R. K. (1983) · Comprehensive biochemistry · doi:10.1016/b978-0-444-80507-2.50011-9 · Cited by 15 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Holmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M., & Davey Smith, G. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00493-1 · Cited by 184 · see citing works
- Authors
- Ordelheide, A.-M., Böhm, A., Kempe-Teufel, D., Wagner, R., Machicao, F., Heni, M., Stefan, N., Fritsche, A., Häring, H.-U., & Staiger, H.
- Affiliations
- Helmholtz Munich (DE)
- Corresponding author
- Staiger, Harald
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-05-04
- Volume
- 12
- Issue
- 5
- Pages
- e0177148
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5417681
- OpenAlex
- W2610402627
- Cited by
- 14
- References
- 15
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 4 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 1
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Site cant be reached (submittedVersion, cc-by)
- Funders
- Bundesministerium für Bildung und Forschung (DE) (01GI0925)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
- Keywords
- SLC5A2, SGLT2, plasma glucagon, glucagon secretion, single nucleotide polymorphisms, genetic association, type 2 diabetes, alpha cells, glucose tolerance, hepatic glucose production, genetic score
- MeSH terms
- Adult, Blood Glucose, Fasting, Female, Glucagon, Glucose, Glucose Tolerance Test, Humans, Insulin, Male, Middle Aged, Risk Factors, Polymorphism, Single Nucleotide, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
